Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 01 December 2016
The US Food and Drug Administration (FDA) on Thursday released a new draft guidance intended to help sponsors report physiologically based pharmacokinetic (PBPK) analyses to the agency in a standardized format.
According to FDA, "PBPK analysis uses models and simulations that combine physiology, population, and drug characteristics to mechanistically describe the [pharmacokinetic] PK and/or pharmacodynamic (PD) behaviors of a drug."
These analyses, FDA says, can also inform other decisions about future clinical pharmacology studies and dosing recommendations, and are often used to support investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs) and abbreviated new drug applications (ANDAs).
"Because of the lack of regulatory guidance, the format and content of PBPK analyses that are submitted to the FDA vary significantly across drug developers," FDA writes.
As such, FDA says it was necessary to standardize the format and content of PBPK study reports in order to improve the agency's efficiency and consistency in assessing them.
In the draft guidance, FDA proposes a six-part format for PBPK study reports that includes a section for an executive summary, introduction, materials and methods, results, discussion and appendices.
However, FDA acknowledges that the amount of data included in each section will vary significantly depending on when the analyses are done, the agency says it still recommends completing each of the sections based on the data available.
Additionally, the section on materials and methods is further broken down into five sub-sections:
While FDA does not have any specific requirements for the software used in PBPK modeling, the agency asks that sponsors submit information on the software they have chosen in a table.
FDA
Tags: Physiology based pharmacokinetics analyses, PBPK
Regulatory Focus newsletters
All the biggest regulatory news and happenings.